What people report
Tirzepatide reviews: what people report
Read 77 people, 4 sitesPublished by PepVault
Of the 77 people whose Tirzepatide write-ups we read, 68 describe a change they wanted (58 a change in weight or appetite; 4 clearer thinking, memory or mood; 4 less pain or faster healing), 1 noticed nothing and 32 describe something unwanted.
What people report
68 of the 77 people describe at least one change they wanted. Each bar counts the people who named anything in that group, once each, out of all 77; the line under it says what they named, and how many named it. 5 of them took Tirzepatide alongside other peptides at the same time.
What went wrong or did nothing
32 of the 77 people describe something they didn’t want, and 1 noticed nothing at all.
Your report
Taken Tirzepatide? What did you notice?
One tap to start. About 30 seconds, no account.

When people say it begins
10 of the 77 people say when they first noticed something; 67 don’t.
What people took it for
46 of the 77 people say what they took it for; 31 don’t.
How it’s thought to work
Shown in people
Tirzepatide acts on two gut-hormone receptors at once, GLP-1 and GIP. Together they slow the stomach, make a meal fill you sooner, quiet hunger in the brain and help the pancreas release insulin when blood sugar rises. Controlled trials in people showed it lowers both body weight and blood sugar; it is approved as Mounjaro for type two diabetes and as Zepbound for weight loss and sleep apnea.
Sources: Jastreboff et al., 2022: SURMOUNT-1, weight in adults without diabetes; Frías et al., 2021: SURPASS-2, blood sugar against semaglutide
What studies show
Our research section has 19 study pages on Tirzepatide: 18 in people and 1 in mice.
The first large trial in people without diabetes gave 2539 adults a weekly shot of tirzepatide or a dummy shot for 72 weeks (SURMOUNT-1); on the highest dose their weight fell by 20.9% on average, against 3.1% on the dummy shot.
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE
- Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeks
- Tirzepatide: sleep apnea gains beat placebo by week 20 in SURMOUNT-OSA
- Tirzepatide: better sleep and quality of life scores in SURMOUNT-OSA
- Tirzepatide: up to 17.5% weight loss at 52 weeks in SURMOUNT-CN
- Tirzepatide: AHI fell 25.3 and 29.3 events per hour in SURMOUNT-OSA
- Tirzepatide: 62% MASH resolution in 15 mg arm vs 10% on placebo
- Tirzepatide 15 mg: 14.7% weight loss at 72 weeks in SURMOUNT-2
- Tirzepatide: HbA1c fell 2.1% vs 1.1% with insulin lispro in SURPASS-6
- Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeks
- Tirzepatide: up to 20.9% weight loss at 72 weeks in SURMOUNT-1
- Tirzepatide: HbA1c fell up to 2.07% at 40 weeks in SURPASS-1
- Tirzepatide beat semaglutide 1 mg on HbA1c at 40 weeks in SURPASS-2
- Retatrutide: 24.1% weight loss in MC4R-deficient mice over 21 days
- Tirzepatide in the library: how it works, half-life and evidence
- Is Tirzepatide legal? FDA, DEA and WADA status
- Tirzepatide dose guide
Where the reports run ahead of the studies
Weight loss, less appetite, lower blood sugar, nausea and constipation are what the controlled trials found too. Where the reports run ahead: 5 of the 77 people describe less wish to drink, which no finished controlled trial of tirzepatide has tested; studies of health records point the same way, and trials are registered (PubMed, searched November 19, 2026).
Where the reports come from
77 people on 45 pages across 4 sites, written from May 2024 to November 2026. Read on November 19, 2026.
The largest single site, the Peptide Critic forum, gave 24 of the 77 (31%).
Peptide Critic, which runs its forum, also runs a shop on its own site that sells injection pens and supplies, not peptides.
Millions of people take tirzepatide on a prescription, and the few who write on these forums are a small corner of them who chose to write. Most Peptide Critic posters took tirzepatide sold for research, and the Diabetes UK posters took Mounjaro on a prescription. On the forums we stopped at about sixty people, the limit we set for every compound.
- Diabetes UK forum, “Has anyone been prescribed Mounjaro?”: 10 people
- rapamycin.news forum, the “Retatrutide” thread: 6 people
- Peptide Critic forum, a thread comparing retatrutide with semaglutide and tirzepatide: 5 people
- rapamycin.news forum, the “Experience with GLP-1s” thread: 5 people
- rapamycin.news forum, the “Tirzepatide” thread: 4 people
- Peptide Critic forum, a thread on split doses: 3 people
- Peptide Critic forum, a thread on tirzepatide with survodutide: 3 people
- Peptide Critic forum, a thread on what retatrutide or tirzepatide changed: 2 people
- Peptide Critic forum, the tirzepatide protocol thread: 2 people
- Peptide Critic forum, a thread on GLP-1 drugs and behaviour: 2 people
- Peptide Critic forum, a thread on vials that seemed weaker: 1 person
- Peptide Critic forum, a thread on switching to tirzepatide: 1 person
- Peptide Critic forum, a Zepbound thread: 1 person
- Peptide Critic forum, a thread on stacking tirzepatide and retatrutide: 1 person
- Peptide Critic forum, a thread where people tell their weight-loss story: 1 person
- Peptide Critic forum, a thread on switching from retatrutide to tirzepatide: 1 person
- Peptide Critic forum, a first progress post: 1 person
- Diabetes UK forum, a thread on a Mounjaro side effect: 1 person
- Diabetes UK forum, a thread on Mounjaro with other diabetes medicines: 1 person
- Diabetes UK forum, a third Mounjaro thread: 1 person
- Diabetes UK forum, a second Mounjaro thread: 1 person
- Diabetes UK forum, a Mounjaro thread: 1 person
- X, public posts: 23 people (post · post · post · post · post · post · post · post · post · post · post · post · post · post · post · post · post · post · post · post · post · post · post)
Read and not counted
- A rapamycin.news member who supplies it to clients: Writes of the clients they sell it to and of their results: the seller’s side of the counter, so not counted.
- A Peptide Critic forum staff member’s posts: The same account posts the forum’s vendor sales roundups, and the site runs its own store: the seller’s side of the counter, so not counted.
- Vendor reviews, telehealth and vial-quality threads on the Peptide Critic forum: Written about a seller, a price or a vial rather than about what the person noticed, so not counted.
- Posts about a stack where the other drug did the work: Where a person put the change down to survodutide, cagrilintide or another drug added to tirzepatide, it is not counted here.
- Reports about someone else (a wife, a husband, a friend, clients): Second-hand; only a person’s own report counts.
- Posts where the drug was unclear (“these meds”, “GLP-1s”): Counted only where the person names tirzepatide, Mounjaro or Zepbound.
- Posts with a plan, a dose question, a price or a supply question and no outcome: Most posts in these threads; nothing noticed was said, either way.
- Drugs.com user reviews: The site refuses automated reads, so it was skipped.
- Patient.info’s community: Searched: almost no first-person Mounjaro posts, so nothing to count.
- LongeCity forum: Searched: no thread of members’ own tirzepatide reports, only a passing mention in an unrelated thread, not read.
- Posts on X from clinics, providers, coaches or sellers, or with no outcome: Clinics and providers explaining it to clients, a coach, a vendor rebrand, someone in the peptide trade, news posts, and questions or plans with nothing noticed; not counted.
- Reddit: Not part of this count.
How we counted
We read every open write-up we could find by people who took Tirzepatide, on its own page, and counted each person once however often they posted, including those who noticed nothing. Sellers, clinics, shop reviews and anyone who earns on a sale are not counted, and neither is a search result’s snippet; the list above names what we read and left out. Write-ups lean positive, because people who notice nothing rarely write about it and expecting an effect can produce one. People on X and on the forums can’t be matched to each other, so someone who wrote in both places may be counted twice.
Spot an error? feedback@pepvault.app. How we research. This page reports what people say; it is not medical advice.